Upfront Briefing
The deal tape kept moving while the biotech tape kept slipping. Hansa cashed €115M out of EU/MENA rights to IDEFIRIX, Regeneron put up to $2.3B behind Parabilis' Helicon platform, and Full-Life pulled in $150M for its Ac-225 pipeline. Underneath it, XBI dropped another 2.3% and NBI -1.9% as a 10Y at 1-year highs and Iran-driven crude squeezed small-cap risk for the second session running. XLV +0.4% confirmed the rotation is into defensive pharma, not biotech beta.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,403.0 |
(0.1%) |
+7.9% |
| Nasdaq 100 |
28,994.4 |
(0.4%) |
+15.0% |
| Russell 2000 |
2,775.1 |
(0.7%) |
+10.6% |
| Healthcare (XLV) |
145.7 |
+0.4% |
(6.3%) |
| Biotech (XBI) |
127.7 |
(2.3%) |
+5.1% |
| Nasdaq Biotech (NBI) |
5,717.6 |
(1.9%) |
+0.2% |
| Clinical Trials (BBC) |
41.2 |
(3.0%) |
+9.4% |
|
- Macro stayed risk-off into a second session: 10Y Treasuries punched a 52-week high (~4.13%), Brent held near $110 on Iran tensions, and tech-led declines dragged Nasdaq 100 and small caps lower while the Dow closed green.
- Biotech beta took the brunt: XBI (2.3%) and NBI (1.9%) extended Friday's FDA-churn sell-off, while XLV +0.4% caught a defensive bid — a ~270bps single-day spread between large-cap pharma and small-cap biotech.
- Market data: U.S. close Mon 18-May-2026.
The Big 3
|
1
|
Hansa Biopharma signs €115M license deal with SERB
|
- Hansa licensed EU, UK, EEA and MENA rights to IDEFIRIX (imlifidase) to SERB for €115M total: €110M upfront and €5M on EMA acceptance of the full approval filing. SERB takes over the PAES and paediatric study upon closing (~60 days); Centerview advised Hansa.
- Why it matters: ~$120M of non-dilutive cash effectively doubles Hansa's ~SEK 700M cash base and de-risks the run-in to the Dec 19 2026 U.S. PDUFA for imlifidase. Hansa keeps the U.S. opportunity (the larger TAM) and offloads a slow-ramping EU franchise hampered by Germany and Spain regional access issues to a specialty rare-disease platform.
- Source: PR
|
|
2
|
Full-Life raises US$150M for clinical assets, manufacturing
|
- Full-Life closed a US$150M package (US$110M Series D equity + US$40M debt) led by Vivo Capital, joined by strategic partner SK Biopharmaceuticals, Chengwei Capital, HSG, Junson Capital and Plaisance among others. Lead assets are [225Ac]-FL-020 (PSMA, mCRPC) and [225Ac]-FL-261 (solid tumors); company targets three clinical-stage programs from its UniRDC platform by year-end.
- Why it matters: Funds the transition from platform builder to clinical-stage radiotherapeutics company in the most heavily M&A'd modality in oncology, and crucially brings the Belgium GMP facility online for global Ac-225 commercial supply — the supply chain that today bottlenecks the entire actinium-based RPT space. ~$350M raised since 2021.
-
Source:
PR
|
| 3 | Regeneron, Parabilis ink up to $2.3B Helicon platform pact |
-
Regeneron and Parabilis Medicines entered a multi-target collaboration to develop Antibody-Helicon Conjugates (AHCs) — stabilised, cell-penetrant alpha-helical peptides paired with Regeneron's VelocImmune antibodies — across five initial intracellular "undruggable" targets. Parabilis gets $50M upfront + $75M equity commitment + up to ~$2.2B in development/regulatory/commercial milestones plus tiered low-double-digit royalties. Regeneron leads all subsequent development and commercialisation.
-
Why it matters:
Regeneron is buying optionality into a new modality class that sits adjacent to ADCs but targets intracellular flat surfaces small molecules can't reach — and at $125M near-term consideration, it's one of the largest preclinical platform deals of 2026. Validates Parabilis' Helicon tech ahead of a likely next round, and signals Regeneron is willing to externally source modality bets beyond its core antibody franchise as it gears up post-Eylea cliff.
-
Source:
PR
Everything Else that broke
- Leads Biolabs gets pivotal Phase III approval in advanced EP-NEC. — PR
- Wave reports positive RestorAATion-2 update for WVE-006 in AATD. — PR
- Mineralys presents new Phase 3 Launch-HTN data for lorundrostat. — PR
- Belite Bio gets Swiss orphan-drug status for tinlarebant. — PR
- Sanofi presents Phase 2 efdoralprin alfa data in AATD. — PR
- Roche tees up ASCO 2026 data for giredestrant in early breast cancer. — PR
- Cullinan to present initial CLN-978 autoimmune data at EULAR 2026. — PR
- Innovent highlights autoimmune and ophthalmology pipeline updates at ATS and ARVO. — PR
- FDA approves AstraZeneca's Baxfendy (baxdrostat) — the first aldosterone synthase inhibitor for uncontrolled/treatment-resistant hypertension; meaningful read-across for Mineralys' lorundrostat. — BioPharma Dive
- Amgen's ANCA-vasculitis drug Tavneos tied to 20 deaths in Japan; adds to prior FDA-flagged VBS cases. — BioSpace
- BioMarin's BMN 401 (ENPP1 deficiency) hits the biomarker co-primary but misses the RGI-C clinical endpoint in ENERGY 3 — raising regulatory path questions for a $270M Inozyme bet; BMRN -2.7%. — PR
- Vincentage's oral GLP-1 VCT220 posts 12.4% weight loss over 52 weeks in 840 Chinese patients — matching orforglipron's highest-dose number and positioning the Chengdu biotech to race Lilly to Chinese regulators. — Fierce
- Truist tags Revolution Medicines as "the next oncology titan", projecting a 2L PDAC approval for daraxonrasib by end of Q3 — after the failed $28-32B Merck talks. — BioSpace
- Accord BioPharma/Intas wins FDA approval for the first golimumab biosimilars, IMMGOLIS and IMMGOLIS INTRI. — PR
- Merck's TROP2 ADC posts an endometrial win. — BioCentury
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Hansa Biopharma signs a €115M license deal with SERB for IDEFIRIX in Europe and MENA. — PR
-
Regeneron and Parabilis ink a multi-target Helicon / Antibody-Helicon Conjugate (AHC) collaboration: $50M upfront + $75M equity + up to ~$2.2B in milestones across 5 initial targets, plus tiered royalties. — PR
-
Neurocrine closed its $2.9B acquisition of Soleno; remaining shares converted to $53.00 cash and Soleno delisted from Nasdaq on May 18. — PR
VC / Private Financings
- Full-Life Technologies raises US$150M (US$110M Series D equity + US$40M debt) led by Vivo Capital, joined by SK Biopharmaceuticals, Chengwei, HSG, Junson, Plaisance, Sky9, TSG and Yunion — funds [225Ac]-FL-020 (prostate), [225Ac]-FL-261 (solid tumors) and Belgium GMP buildout. — PR
IPOs / Follow-Ons
- No new biotech IPOs or material follow-ons priced.
Academic Corner - Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy. — Nature Biotech
|
